Data updated: Mar 10, 2026
WIDAPLIK
AMLODIPINE BESYLATE
Approved 2025-06-05
1
Indication
--
Phase 3 Trials
0
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2025-06-05
- Routes
- ORAL
- Dosage Forms
- TABLET
WIDAPLIK Approval History
Loading approval history...
What WIDAPLIK Treats
1 FDA approvalsOriginally approved for its first indication in 2025 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
WIDAPLIK FDA Label Details
ProWIDAPLIK Patents & Exclusivity
Latest Patent: Jan 2038
Exclusivity: Jun 2028
Patents (12 active)
US10799487
Expires Jan 23, 2038
US10322117
Expires Jan 23, 2038
US12465599
Expires Jan 23, 2038
+ 2 more patents
Exclusivity
NP
Until Jun 2028
NP
Until Jun 2028
NP
Until Jun 2028
NP
Until Jun 2028
NP
Until Jun 2028
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.